BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 221 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $166,800 | -96.0% | 20,000 | -94.6% | 0.01% | -96.3% |
| Q4 2022 | $4,216,604 | -24.3% | 367,300 | -16.9% | 0.37% | -31.5% |
| Q3 2022 | $5,568,000 | +19.1% | 441,900 | 0.0% | 0.55% | +28.5% |
| Q2 2022 | $4,675,000 | -35.2% | 441,900 | -0.3% | 0.42% | -24.4% |
| Q1 2022 | $7,210,000 | +15.7% | 443,400 | -1.4% | 0.56% | +28.9% |
| Q4 2021 | $6,230,000 | -2.1% | 449,800 | +1.6% | 0.44% | -15.7% |
| Q3 2021 | $6,364,000 | -7.8% | 442,900 | +1.4% | 0.52% | -5.7% |
| Q2 2021 | $6,904,000 | +55.8% | 436,690 | +0.2% | 0.55% | +31.1% |
| Q1 2021 | $4,432,000 | +98.2% | 435,790 | +45.2% | 0.42% | +79.4% |
| Q4 2020 | $2,236,000 | +272.0% | 300,190 | +71.5% | 0.23% | +228.2% |
| Q3 2020 | $601,000 | +214.7% | 175,000 | +337.5% | 0.07% | +184.0% |
| Q2 2020 | $191,000 | – | 40,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 1,105,673 | $8,237,000 | 6.28% |
| Sarissa Capital Management LP | 8,175,000 | $60,903,000 | 6.22% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,980,870 | $22,207,000 | 2.78% |
| DG Capital Management, LLC | 1,075,732 | $8,014,000 | 1.70% |
| Ghost Tree Capital, LLC | 900,000 | $6,705,000 | 1.49% |
| Parkman Healthcare Partners LLC | 538,370 | $4,011,000 | 1.03% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,835,810 | $43,477,000 | 0.86% |
| Formidable Asset Management, LLC | 470,419 | $3,470,000 | 0.80% |
| KNOTT DAVID M | 219,461 | $1,635,000 | 0.74% |
| Altium Capital Management LP | 250,000 | $1,863,000 | 0.70% |